Liquidia Corporation Prepares for Financial Results Announcement
Liquidia Corporation, a biopharmaceutical company dedicated to advancing therapies for rare cardiopulmonary diseases, is gearing up to release its financial performance results for the third quarter of 2024. This key event is scheduled for a Monday morning and marks a significant point in the company’s financial calendar.
Details of the Financial Results Announcement
The announcement of the financial results will take place during a live webcast at 8:30 a.m. Eastern Time. This presentation is not only an opportunity for the company to share its financial performance but also to provide essential updates regarding its corporate activities and advancements within its product pipeline.
How to Access the Live Webcast
Interested investors and stakeholders can access the live webcast directly on Liquidia's official website. After the initial broadcast, a recorded version of the event will also be available for viewing, extending accessibility for those unable to attend the live session. This makes it convenient for all interested parties to stay informed about the company’s strategy and performance.
About Liquidia Corporation's Innovative Solutions
Liquidia Corporation's mission centers on developing groundbreaking therapies tailored to treat rare cardiopulmonary diseases. At the heart of their focus is the proprietary PRINT Technology which allows for the formulation of precise medication delivery systems. Currently, the company’s flagship product is YUTREPIA™ (treprostinil) inhalation powder, a promising treatment aimed at pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Current Projects and Future Directions
In addition to YUTREPIA™, Liquidia is also working on L606, an investigational sustained-release formulation of treprostinil designed to be used with a next-generation nebulizer, representing another potential advancement in patient care. Furthermore, the company markets a generic version of Treprostinil Injection for PAH treatment, diversifying its offerings and enhancing accessibility to vital therapies for patients.
Contacting Liquidia Corporation for More Information
For those seeking additional information about Liquidia Corporation, the company has designated resources to assist both investors and media representatives. Jason Adair serves as the Chief Business Officer for investor inquiries, while Patrick Wallace leads corporate communications, ensuring that all stakeholder concerns are addressed efficiently.
Connecting with the Team
Both investors and media outlets can reach out directly via the provided contact details for any specific questions or further insights regarding ongoing projects or financial matters. Liquidia is committed to maintaining transparency and keeping its stakeholders informed about significant developments.
Frequently Asked Questions
What date will Liquidia Corporation announce its financial results?
Liquidia Corporation will report its third quarter 2024 financial results on a Monday in November.
Where can I watch the financial results webcast?
The webcast will be accessible on Liquidia's official website during the scheduled time.
What is Liquidia Corporation known for?
Liquidia Corporation specializes in developing innovative therapies for patients suffering from rare cardiopulmonary diseases.
Who should I contact for investor inquiries?
For investor inquiries, please contact Jason Adair, the Chief Business Officer.
What is YUTREPIA™?
YUTREPIA™ is an inhalation powder for treating pulmonary arterial hypertension, developed by Liquidia Corporation.